This biotech is using the chromatin regulatory system to fight back against cancer
Foghorn Therapeutics recently announced dosing of the first patient in the Phase 1 trial of FHD-909 in collaboration with Eli Lilly.
Company: Foghorn Therapeutics
1 story
Make us preferred on Google